drugset / Trial / NCT04671303
To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This Study is To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule Combined with Furmonertinib Mesylate in First-line Treatment of Advanced no-squamous and No-small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2023-06-30
- Completion
- 2023-07-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | Oral |
| Subject | Firmonertinib | Small molecule | 80 mg | Oral |